178 related articles for article (PubMed ID: 12919325)
1. The CRIPTO/FRL-1/CRYPTIC (CFC) domain of human Cripto. Functional and structural insights through disulfide structure analysis.
Foley SF; van Vlijmen HW; Boynton RE; Adkins HB; Cheung AE; Singh J; Sanicola M; Young CN; Wen D
Eur J Biochem; 2003 Sep; 270(17):3610-8. PubMed ID: 12919325
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into the interaction between the Cripto CFC domain and the ALK4 receptor.
Calvanese L; Saporito A; Oliva R; D' Auria G; Pedone C; Paolillo L; Ruvo M; Marasco D; Falcigno L
J Pept Sci; 2009 Mar; 15(3):175-83. PubMed ID: 19035567
[TBL] [Abstract][Full Text] [Related]
3. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
4. Chemical synthesis of mouse cripto CFC variants.
Marasco D; Saporito A; Ponticelli S; Chambery A; De Falco S; Pedone C; Minchiotti G; Ruvo M
Proteins; 2006 Aug; 64(3):779-88. PubMed ID: 16752415
[TBL] [Abstract][Full Text] [Related]
5. Subtractive hybridization identifies chick-cripto, a novel EGF-CFC ortholog expressed during gastrulation, neurulation and early cardiogenesis.
Colas JF; Schoenwolf GC
Gene; 2000 Sep; 255(2):205-17. PubMed ID: 11024280
[TBL] [Abstract][Full Text] [Related]
6. Chemical synthesis, structural modeling, and biological activity of the epidermal growth factor-like domain of human cripto.
Lohmeyer M; Harrison PM; Kannan S; DeSantis M; O'Reilly NJ; Sternberg MJ; Salomon DS; Gullick WJ
Biochemistry; 1997 Apr; 36(13):3837-45. PubMed ID: 9092813
[TBL] [Abstract][Full Text] [Related]
7. Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells.
Parisi S; D'Andrea D; Lago CT; Adamson ED; Persico MG; Minchiotti G
J Cell Biol; 2003 Oct; 163(2):303-14. PubMed ID: 14581455
[TBL] [Abstract][Full Text] [Related]
8. Solution structure of mouse Cripto CFC domain and its inactive variant Trp107Ala.
Calvanese L; Saporito A; Marasco D; D'Auria G; Minchiotti G; Pedone C; Paolillo L; Falcigno L; Ruvo M
J Med Chem; 2006 Nov; 49(24):7054-62. PubMed ID: 17125258
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of small bicyclic peptide inhibitors of Cripto-1 activity.
Iaccarino E; Calvanese L; Untiveros G; Falcigno L; D'Auria G; Latino D; Sivaccumar JP; Strizzi L; Ruvo M; Sandomenico A
Biochem J; 2020 Apr; 477(8):1391-1407. PubMed ID: 32215602
[TBL] [Abstract][Full Text] [Related]
10. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells.
Bianco C; Adkins HB; Wechselberger C; Seno M; Normanno N; De Luca A; Sun Y; Khan N; Kenney N; Ebert A; Williams KP; Sanicola M; Salomon DS
Mol Cell Biol; 2002 Apr; 22(8):2586-97. PubMed ID: 11909953
[TBL] [Abstract][Full Text] [Related]
11. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
Gray PC; Harrison CA; Vale W
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
[TBL] [Abstract][Full Text] [Related]
12. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.
Kelber JA; Shani G; Booker EC; Vale WW; Gray PC
J Biol Chem; 2008 Feb; 283(8):4490-500. PubMed ID: 18089557
[TBL] [Abstract][Full Text] [Related]
13. Cripto localizes Nodal at the limiting membrane of early endosomes.
Blanchet MH; Le Good JA; Oorschot V; Baflast S; Minchiotti G; Klumperman J; Constam DB
Sci Signal; 2008 Nov; 1(45):ra13. PubMed ID: 19001664
[TBL] [Abstract][Full Text] [Related]
14. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway.
Yan YT; Liu JJ; Luo Y; E C; Haltiwanger RS; Abate-Shen C; Shen MM
Mol Cell Biol; 2002 Jul; 22(13):4439-49. PubMed ID: 12052855
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and Cellular Analysis Reveals Ligand Binding Specificities, a Molecular Basis for Ligand Recognition, and Membrane Association-dependent Activities of Cripto-1 and Cryptic.
Aykul S; Parenti A; Chu KY; Reske J; Floer M; Ralston A; Martinez-Hackert E
J Biol Chem; 2017 Mar; 292(10):4138-4151. PubMed ID: 28126904
[TBL] [Abstract][Full Text] [Related]
16. Investigating the oxidative refolding mechanism of Cripto-1 CFC domain.
Iaccarino E; Sandomenico A; Corvino G; Focà G; Severino V; Russo R; Caporale A; Raimondo D; D'Abramo M; Alba J; Chambery A; Ruvo M
Int J Biol Macromol; 2019 Sep; 137():1179-1189. PubMed ID: 31295488
[TBL] [Abstract][Full Text] [Related]
17. Structural investigations on the Nodal-Cripto binding: a theoretical and experimental approach.
Calvanese L; Marasco D; Doti N; Saporito A; D'Auria G; Paolillo L; Ruvo M; Falcigno L
Biopolymers; 2010 Nov; 93(11):1011-21. PubMed ID: 20629020
[TBL] [Abstract][Full Text] [Related]
18. Role of the EGF-CFC gene cripto in cell differentiation and embryo development.
Minchiotti G; Parisi S; Liguori GL; D'Andrea D; Persico MG
Gene; 2002 Apr; 287(1-2):33-7. PubMed ID: 11992720
[TBL] [Abstract][Full Text] [Related]
19. Fucosylation of Cripto is required for its ability to facilitate nodal signaling.
Schiffer SG; Foley S; Kaffashan A; Hronowski X; Zichittella AE; Yeo CY; Miatkowski K; Adkins HB; Damon B; Whitman M; Salomon D; Sanicola M; Williams KP
J Biol Chem; 2001 Oct; 276(41):37769-78. PubMed ID: 11500501
[TBL] [Abstract][Full Text] [Related]
20. Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro.
Focà G; Iaccarino E; Focà A; Sanguigno L; Untiveros G; Cuevas-Nunez M; Strizzi L; Leonardi A; Ruvo M; Sandomenico A
Biochimie; 2019 Mar; 158():246-256. PubMed ID: 30703478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
